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Abstract
Subarachnoid hemorrhage after the rupture of a cerebral aneurysm is the cause of 6% to 8% of all cerebrovascular
accidents involving 10 of 100,000 people each year. Despite effective treatment of the aneurysm, delayed cerebral
ischemia (DCI) is observed in 30% of patients, with a peak on the tenth day, resulting in significant infirmity and
mortality. Cerebral vasospasm occurs in more than half of all patients and is recognized as the main cause of
delayed cerebral ischemia after subarachnoid hemorrhage. Its treatment comprises hemodynamic management
and endovascular procedures. To date, the only drug shown to be efficacious on both the incidence of vasospasm
and poor outcome is nimodipine. Given its modest effects, new pharmacological treatments are being developed
to prevent and treat DCI. We review the different drugs currently being tested.
Introduction
Delayed cerebral ischemia (DCI) is a common and ser-
ious complication following subarachnoid hemorrhage
(SAH) after ruptured cerebral aneurismal [1,2].
Although this complication is at times reversible, it
may develop into a cerebral infarction [3]. DCI occurs
in approximately 20% to 40% [4] of patients and is
associated with increased mortality and poor prognosis
[5,6]. It is usually caused by a vasospasm [7], which,
although preventable, remains a major cause of poor
neurological outcome and increased mortality in the
course of SAH [4-6].
Vasospasm is defined as a reversible narrowing of the
subarachnoid arteries occurring between the third to
fifth and fifteenth day after the hemorrhage, with a peak
at the tenth day. It is observed in 70% of patients on
angiographic scans and causes symptoms in 50% [7-10].
Angiographic vasospasm is defined as evidence of arter-
ial narrowing compared with the parent vessels [11]. It
preferentially involves the vessels of the cranial base but
also may affect small-caliber vessels or diffusely the
entire cerebral vascularization. The severity of vasos-
pasm is variable. The subsequent decrease in cerebral
blood flow (CBF) in the spastic arteries leads to DCI,
which may develop into cerebral infarction [7,12,13].
The etiology of vasospasm is complex and still poorly
understood. Several factors have been shown to be
involved, such as endothelial dysfunction, loss of autore-
gulation, and a hypovolemic component leading to a
decrease in CBF [14-16]. At the acute phase, the pre-
sence of oxyhemoglobin in the subarachnoid spaces
causes a local and systemic inflammatory reaction [17]
with activation of platelets and coagulation [8-10]. The
products derived from red blood cells (bilirubin) and
endothelium (endothelin-1, free radicals) are considered
to be mediators of the vasospasm [18-22] Structural
anomalies in endothelial and smooth muscle cells also
have been reported [23].
Treatments of DCI consist of preventing or minimiz-
ing secondary injuries by means of hemodynamic man-
agements, pharmacological agents, and endovascular
procedures [12,24,25]. Although these measures result
in a decrease in the incidence of vasospasm, the prog-
nostic of DCI remain unchanged [5,24].
Because SAH is frequently accompanied by cerebral
autoregulation impairment, hypotension should be
avoided. To achieve an adequate cerebral perfusion
pressure, triple H therapy was designed to induce
volume expansion, rheology improvement, and blood
pressure increase. Hence, systolic arterial pressure is
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aneurysm is secured [26]. Before treating aneurysm, it is
nevertheless mandatory to maintain systolic blood pres-
sure at lower levels than 150 mmHg. However, there is
now evidence suggesting that blood pressure increase is
the most important part of those measures because
hypervolemia does not have any benefit on cerebral
blood flow and tissue oxygenation.
Although triple H therapy reverses deficits associated
with vasospasm, it has not been shown to decrease DCI
occurrence or mortality [27].
Besides hemodynamic treatment, various pharmacolo-
gical treatments have been tested [28,29]. Nimodipine is
the currently recommended drug [30]. Given its rela-
tively modest effects, new treatments have been
developed.
We review recent literature pertaining to the different
drugs being used or under evaluation.
Calcium channel blockers
Nimodipine is a voltage-gated calcium channel antago-
nist that inhibits calcium entry into smooth muscle cells
and neurons. Its lipophilic properties allow it to cross
the hematoencephalic barrier. Prophylactic administra-
tion of nimodipine was shown to be efficacious in
decreasing the risk of secondary ischemia and poor out-
come [31,32]. The latest guidelines of the American
Stroke Association recommend the oral administration
of nimodipine at the dose of 60 mg every 4 hours for 21
days starting from the admission into the intensive care
unit (Class I, Level of evidence A) [29].
The proof of its efficacy is based on four randomized,
placebo-controlled trials of 853 patients, showing an
improvement in functional outcome [32-36]. None of
the studies were able to demonstrate a reduction in
angiographic vasospasm [31]. Its benefits seem to derive
from neuroprotective properties rather than its vasodila-
tory effects. The exact mechanism preventing and limit-
ing the extension of ischemic lesions remains unknown.
In experimental models, nimodipine has been shown to
attenuate the neuronal calcium increase after cellular
ischemia and causing cell death [37].
Whereas calcium is recognized to play a significant
role in the occurrence of vasospasm, other elements,
such as inflammatory mediators, blood rheology, or
microcirculation disturbances, are to be considered.
Oxyhemoglobin, for example, causes a decreased activity
of potassium channels, which may lead to membrane
depolarization and consecutive vasoconstriction [2].
Nimodipine has been shown to be safe [38] and cost-
effective [39] without any effect on mortality. Hypoten-
sion is a rarely reported side-effect. The current recom-
mendations are based on data pertaining to oral
administration of nimodipine. A recent study attempted
to show that nimodipine’s intravenous use would be
associated with similar beneficial effects [40], although
this mode of administration is more often linked to
hypotension [41].
Among the other tested calcium channel antagonists,
nicardipine was shown to decrease symptomatic vasos-
pasm [39,42] but without having any effect on DCI and
outcome. The prophylactic use of diltiazem was investi-
gated in a single monocenter study [43]. The rate of
favorable outcome was 74.8%.
During endovascular procedures, intra-arterial infusion
of nicardipine [44], nimodipine [45], and diltiazem [46]
were shown to reduce vasospasm with favorable effects
on DCI. However, randomized control studies are still
needed (Class IIb, Level of evidence B).
Lastly, two studies showed that prolonged-release
nicardipine-loaded polymers implanted upon aneurysmal
clipping decreased vasospasm and DCI and improved
outcome [38,47]. This mode of administration is pro-
mising, although further investigations are necessary.
Tirilazad
Tirilazad mesylate is a neuroprotective corticosteroid
whose efficacy was demonstrated in animal stroke mod-
els [48]. It has antioxidant properties that block free
radical-induced peroxidation of membrane lipids, which
has been shown to facilitate vasospasm. The compound
was evaluated in combination with nimodipine in five
randomized, double-blind, placebo-controlled trials on a
total of 3,821 patients, but no benefit was noted on DCI
or outcome [49-52]. Therefore, this drug is not
recommended.
Statins
Statins are inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A, responsible for cholesterol synthesis [53].
In addition, statins display pleiotropic effects, such as
anti-inflammatory effects, a stabilizing effect on athero-
matous plaques, and anti-adhesive effects on endothe-
lium. Neuroprotective activity also was reported [54,55].
Animal experiments showed a lower incidence of
vasospasm when simvastatin therapy was initiated at the
time of SAH [56,57]. This beneficial effect is assumed to
be due to increased nitric oxide (NO) production on
account of NO synthesis induction [58], with subse-
quent vasodilatation likely to improve CBF.
Several retrospective studies demonstrated that
patients treated with statins before SAH presented less
DCI and fewer cerebral infarctions [59]. Conversely,
other retrospective investigations did not reveal any sta-
tin-induced benefits on vasospasm and outcome [60].
Two prospective phase II studies with 80 and 39
patients treated by simvastatin and pravastatin, respec-
tively, revealed a reduction in vasospasm, a decrease in
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[61,62]. The use of statins deemed safe in both studies.
Nevertheless, the subsequent studies were not able to
confirm the benefits of statin therapy. Two prospective,
placebo-controlled trials using simvastatin on a small
number of patients in addition [63,64] to three observa-
tional studies with a historic control revealed no
improvement in vasospasm incidence, DCI, or outcome
[59,60,65].
Even if the most recent meta-analysis did not confirm
the significant effect of statins [66], it should be noted
that the trial results are difficult to interpret given the
variable disease severity int h ec o n t r o lg r o u p sa n dt h e
differing methodologies used. Moreover, it is hazardous
to draw conclusions on the basis of four placebo-con-
trolled trials that included only 190 patients. The poten-
tial advantage of statins cannot be ruled out. In light of
their potential benefits, the current recommendations
[29] state that statins may be initiated in patients with
SAH (Class IIb, Level of evidence B).
Presently ongoing is a multicenter phase III study on
1,600 SAH patients: STASH (Simvastatin in Aneurysmal
Subarachnoid Hemorrhage). This investigation was
designed to assess the effects of simvastatin given at a
40-mg dose for 21 days versus placebo. The primary
evaluation criterion is functional outcome at 6 months
using the modified Rankin disability score (mRS).
Magnesium sulfate
Magnesium exerts vasodilatory effects by blocking vol-
tage-gated calcium channels. Hypomagnesemia occurs
in 38% of SAH patients and is a predictor of DCI [67].
Based on animal experimental models supporting its
neuroprotective activity [68], magnesium could be
instrumental in improving vasospasm and limiting cer-
ebral ischemia in humans. Although clinical studies
have demonstrated that magnesium is safe, they were
not able to confirm its efficacy clearly. The first clinical
trials showed a trend toward reduced DCI and
improved outcome [69]. The randomized, double-
blind, placebo-controlled MASH (Magnesium in
Aneurysmal Subarachnoid Hemorrhage) study, includ-
ing 283 patients revealed reduced DCI and improved
outcome at 3 months, but the differences with placebo
did not reach statistical significance [70]. Another
s t u d yu s i n gt h es a m ed e s i g na n di n v o l v i n g6 0p a t i e n t s
showed a significant reduction in vasospasm duration
assessed by ultrasounds, but no difference in outcome
at 6 months [71].
Given that few studies obtained sufficient statistical
strength, further clinical trials continue to be underta-
ken. The multicentre IMASH (Intravenous Magnesium
Sulphate for Aneurysmal Subarachnoid Haemorrhage)
study reevaluated the effect of magnesium on 327
patients using a prospective, double-blind, placebo-con-
trolled design. No difference in outcome was observed
at 6 months, nor was there any effect on clinical vasos-
pasm [72]. The results from another large multicenter
study (MASH-II) are expected soon. Even though a few
studies reported the occurrence of hypotension, data
concerning its impact on DCI and outcome is still lack-
ing [73].
Although magnesium cannot be explicitly recom-
mended at present, it may exert neuroprotective activity,
independently from the occurrence of vasospasm. In
fact, the concept of predicting DCI in relation to the
occurrence of vasospasm must be put into perspective.
Given that endothelial dysfunction is the cause of cere-
bral perfusion problems, magnesium may play an impor-
tant role, independently from its vasodilatory effects,
although its mechanism is not yet understood. It has
been shown to be protective in other types of brain
injury, such as acute ischemic stroke [74].
Endothelin-1 antagonist
Endothelin (ET) is a powerful vasoconstrictor [75]. Its
receptors are situated on smooth muscle cells (ET
receptor ETA and ETB2) and endothelium (ET receptor
ETB1). The isoform 1 (ET-1) displays a more significant
effect on cerebral arteries, and elevated ET-1 levels were
observed in plasma and CSF (cerebrospinal fluid) after
SAH [76]. ET-1 has been suggested to largely contribute
to vasoconstriction-vasodilatation imbalance during
SAH [77,78].
ET-1 receptor blockers have been developed and suc-
cessfully tested in animals [79]. The first nonselective
antagonist (TAK-044) was evaluated, showing a decrease
in ischemic events at 3 months in 420 patients [80]. A
selective ETA antagonist (clazosentan) was shown to
decrease the frequency and severity of vasospasm in a
p r e l i m i n a r yp h a s eI I as t u d y[ 8 1 ] .T h r e ed o s e so fc l a z o -
sentan were recently tested on 413 patients in a rando-
mized, double-blind, placebo-controlled study
(CONSCIOUS-1: Clazosentan to Overcome Neurologi-
cal Ischemia and Infarction Occurring after Subarach-
noid Haemorrhage) [82]. The treatment was initiated
within the first 56 hours and continued for 14 days. The
aneurysmal treatment was conducted before or in the
first 12 hours after administering clazosentan.
A dose-dependent decrease in angiographic vasospasm
was observed. No benefit was noted on outcome,
although this was not the primary evaluation criterion
of the study. In post-hoc analyses, a trend toward
improved clinical outcome was reported. Clazosentan
was associated with an increased frequency of side-
effects, such as hypotension, anaemia, and pulmonary
infections. In addition, an increase in mortality was
found in the active-treatment group. The majority of
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phase III studies (CONSCIOUS-2 and CONSCIOUS-3)
are currently ongoing in patients treated using clipping
or coiling [83].
Fasudil
Fasudil is a rho-kinase inhibitor, an enzyme involved in
the contraction of smooth muscle cells [84]. The inhibi-
tion of the rho-kinase pathway causes cellular relaxation.
Fasudil, initially investigated in Japan on 276 patients,
was shown to reduce vasospasm but without any effect
on outcome [85]. However, when administered intra-
arterially in combination with the drainage of intracis-
ternal clots and intracisternal urokinase injection, fasudil
appeared to reduce the incidence of vasospasm and
improve outcome. A recent review of 90 cases seemed
to indicate that this procedure was safe and effective on
vasospasm and DCI [86]. Further investigations are
therefore necessary.
Antiplatelet therapy
Due to the formation of microthrombi and secretion of
thromboxane A2, platelet aggregation may play a role in
DCI. Seven randomized and controlled trials involving
1,385 patients tested the effect of antiplatelet agents
(acetylsalicylic acid or ticlopidine). However, none
revealed any benefit on DCI or patient outcomes [87].
Enoxaparin
A single study tested the effect of low-molecular-weight
heparin following SAH. In a randomized, double-blind,
single-center trial of 170 patients, enoxaparin was admi-
nistered 24 hours after aneurysm treatment and contin-
ued for 10 days. There was no benefit on outcome at 3
months [88]. In addition, cerebral bleeding rate was
increased with enoxaparin.
Albumin
The neuroprotective activity of albumin was suggested
in different types of brain injury, such as cranial trauma,
cerebral ischemia, and SAH [89]. Albumin demonstrated
improved CBF in a dog model of SAH [90]. Human data
suggest that albumin has protective effects in ischemic
stroke [91].
A retrospective study comparing albumin 25% and
0.9% NaCl administered for intravascular filling revealed
improved outcome at 3 months in the albumin-treated
group, whereas the incidence of vasospasm did not dif-
fer [92]. A prospective, multicenter study, Albumin in
Subarachnoid Haemorrhage (ALISAH), designed to
demonstrate the tolerability and safety of four doses of
albumin is currently in progress [93]. This study has
been designed to determine the maximally tolerated
dose without provoking cardiac decompensation and
pulmonary edema. An evaluation of neurological dete-
riorations is performed at 15 days and 3 months. The
toxin-scavenging action of albumin has already been
described in numerous diseases [94]. It is possible that
albumin acts by scavenging mediators of endothelial
dysfunction, such as free radicals.
Nitric oxide donors
An alteration in NO production is an important
mechanism in vasospasm etiology [95,96]. A decrease in
NO synthesis during SAH has been noted and is
responsible for deficient vessel relaxation and a subse-
quent decline in CBF [97]. The concept of NO donors
was proposed as treatment for refractory vasospasm.
Different modes of administration were tested: intrave-
nous, intra-arterial, and intrathecal [2,98]. Intraventricu-
lar administration of sodium nitroprusside was shown to
improve vasospasm and CBF, although side-effects were
common [99]. One study suggested an improvement in
outcome [100], whereas another involving a small num-
ber of patients did not reveal any effect of transdermal
nitroglycerin [101]. Currently, NO donors have a limited
place in DCI treatment, and further investigations are
needed.
Erythropoietin
Erythropoietin (EPO) is an amino acid sialoglycoprotein
s e c r e t e db yt h ek i d n e ya n dk n o w nt op l a yar o l ei n
hematopoiesis [102]. EPO receptors have been found in
a large number of tissues other than bone marrow, and
its neuroprotective role has been suggested [103]. In
vitro experiments and animal studies showed that EPO
enhances neuronal survival under stress situations, such
as excitotoxicity [104] and ischemia [105,106]. EPO
doses must be sufficiently high due to its weak capacity
to cross the blood-brain barrier [107]. The proposed
mechanisms are diverse, including anti-inflammatory
and anti-apoptotic roles, and modulating NO produc-
tion [108].
Two double-blind placebo-controlled trials were con-
ducted involving 73 and 80 patients, respectively
[109,110]. Tseng et al. showed that patients treated with
EPO had a lower incidence of severe vasospasm (27.5
vs. 7.5%), reduced DCI (40 vs. 7.5%), and improved out-
come [105]. Even if the number of investigated patients
is still low, EPO is considered to be a promising mole-
cule given its beneficial effects at the acute SAH phase
and its protective effects at the ischemic phase.
Intracisternal thrombolytics
An etiological role was attributed to spasmogenic sub-
stances released from clots in the subarachnoid spaces.
Of note is that the quantity of blood is considered to be
a predictor of vasospasm [111]. The intraventricular
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ment. To date, two types of thrombolytics have been
tested: urokinase and t-PA (tissue plasminogen activa-
tor). The analysis of reported cases suggests a beneficial
effect, although it is limited due to the small number of
randomized studies [112]. Only one double-blind, pla-
cebo-controlled trial assessed the peroperative adminis-
tration of t-PA on 100 patients [113]. No clear benefit
was found with respect to vasospasm and DCI; only
patients showing large clots experienced a decrease in
vasospasm. The use of this technique requires further
prospective studies to define optimal timing, mode of
administration, and the type of patients likely to benefit
the most. The low incidence of reported complications
encourages the undertaking of new studies.
Conclusions
The poor prognosis of patients with DCI following SAH
remains a major issue responsible for death and infir-
mity. Although our understanding of the physiopathol-
ogy of DCI and vasospasm has improved, patient
outcome has not been significantly modified. Manage-
ment currently focuses on CBF improvement along with
hemodynamic manipulation and endovascular proce-
dures. The only recommended pharmacological treat-
ment is nimodipine.
Although the different compounds tested mostly show
ad e c l i n ei nt h ei n c i d e n c eo fr a d i o g r a p h i cv a s o s p a s m ,
they do not impact on outcome. New pharmacological
treatments with neuroprotective effects, such as statins,
magnesium, and endothelin inhibitors, revealed promis-
ing results. However, the lack of randomized designs
and insufficient statistical power of these studies do not
allow us to recommend these medications in SAH man-
agement at the present time.
The disassociation of vasospasm and clinical outcome
also is linked to the fact that DCI occurring after SAH
is a multifactorial process without being restricted to
arterial narrowing. Effectively, DCI may not only be pre-
dicted by cerebral vessels caliber alone; it also may
occur in the absence of major vasospasm.
Future investigations should allow us to better under-
stand the mechanisms of endothelial dysfunction, such
as oxidative stress, inhibition of vasodilation, and the
secretion of vasoconstrictors. The physiopathology of
microcirculation dysfunction is all the more complex as
unspecific phenomena, such as inflammation, platelet
activation, and microthrombi formation. In addition,
vasoconstrictors, such as norepinephrine, may have
paradoxical effects, and their impact on cerebral micro-
circulation has not been determined yet.
There is evidence supporting the use of neuroprotec-
tive agents. The results of ongoing randomized studies
will confirm or not the efficacy of these new
treatments. While awaiting potential benefits from
neuroprotective treatments, the standard management
of intensive care patients using specifically metabolic
and ionic control as well as temperature maintenance
is still required to preserve the damaged brain. Fever is
a common complication and is related to prognosis
during the first 2 weeks after SAH [114]. If hyperther-
mia should be avoided in a patient with increased
intracranial pressure, early fever control after SAH
could be associated with improved outcome. Recent
retrospective data have shown that temperature main-
tenance above 37°C during the first 2 weeks may be
associated with a better outcome [115].
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